Tema Oncology ETF Rating $26.39 +0.09 (+0.34%) (As of 11:19 AM ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrends Tema Oncology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.77Holdings in CANC have an aggregate rating of Moderate Buy based on 604 analyst ratings issued in the past year covering 44 companies (83.1% of the portfolio).CANC Aggregate Price Target$26.43High Prediction$26.43Average Prediction$26.43Low Prediction$26.43Holdings in CANC have an aggregate price target of $26.43 and a range of $26.43 to $26.43 covering 44 companies (83.1% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy13 Buy rating(s)Moderate Buy27 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 44 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.59%REGNRegeneron Pharmaceuticals$743.45+0.0%4.8024 of 5 stars2.78$1,099.55 47.9%23Positive News5.41%AMGNAmgen$287.16-0.2%4.9132 of 5 stars2.46$333.57 16.2%26Ex-DividendShort Interest ↓Positive News4.72%GILDGilead Sciences$88.83+0.2%4.6461 of 5 stars2.65$94.45 6.3%26Analyst UpgradePositive News3.95%RVMDRevolution Medicines$57.67+1.1%2.7998 of 5 stars3.08$61.00 5.8%123.88%ILMNIllumina$133.37+1.3%4.5888 of 5 stars2.67$164.00 23.0%24Positive News3.81%ARGXargenx$588.56-0.6%2.8276 of 5 stars2.91$630.42 7.1%23Analyst Forecast3.79%INCYIncyte$70.00-1.5%3.912 of 5 stars2.38$77.16 10.2%21Analyst Forecast3.08%BPMCBlueprint Medicines$95.47+0.7%2.7179 of 5 stars2.71$122.11 27.9%21Analyst ForecastAnalyst Revision2.73%MREOMereo BioPharma Group$3.61+0.8%2.9754 of 5 stars3.20$7.50 107.8%5Analyst RevisionNews Coverage2.51%BGNEBeiGene$193.14-0.6%3.1938 of 5 stars2.71$247.07 27.9%7Analyst Downgrade2.37%MRKMerck & Co., Inc.$98.22+0.8%4.9964 of 5 stars2.68$130.86 33.2%19Dividend IncreasePositive News2.35%CRSPCRISPR Therapeutics$46.22-2.2%1.788 of 5 stars2.37$74.94 62.1%192.35%EXELExelixis$34.69+0.1%4.7895 of 5 stars2.65$31.44 -9.4%20Insider Trade2.24%EXASExact Sciences$53.43+1.4%4.8873 of 5 stars2.95$74.47 39.4%19Analyst ForecastPositive News2.24%AGIOAgios Pharmaceuticals$54.37-0.5%3.3124 of 5 stars2.50$52.33 -3.7%81.96%NUVLNuvalent$92.53+1.5%2.1777 of 5 stars2.85$112.60 21.7%131.96%GMABGenmab A/S$20.40-0.2%4.3164 of 5 stars2.60$45.20 121.6%101.86%DAWNDay One Biopharmaceuticals$13.36-1.9%2.0003 of 5 stars3.00$35.71 167.3%9Positive News1.63%LNTHLantheus$87.50+1.2%4.5969 of 5 stars2.89$122.50 40.0%9Positive News1.57%LEGNLegend Biotech$39.92-0.5%1.7671 of 5 stars3.00$81.46 104.1%13Analyst Revision1.53%NTLAIntellia Therapeutics$14.06+7.2%4.5424 of 5 stars2.72$54.94 290.7%18Analyst ForecastAnalyst Revision1.48%JANXJanux Therapeutics$48.17-1.6%3.5987 of 5 stars2.90$66.44 37.9%101.47%CLDXCelldex Therapeutics$26.68+1.1%2.8782 of 5 stars2.89$62.25 133.3%9Analyst ForecastNews Coverage1.46%GHGuardant Health$30.46-0.7%4.2853 of 5 stars2.94$40.60 33.3%161.40%MRUSMerus$43.91+2.3%3.0028 of 5 stars3.14$85.45 94.6%14Analyst ForecastNews CoverageGap Up1.35%ACLXArcellx$87.58+0.4%2.9324 of 5 stars3.07$103.08 17.7%14Short Interest ↓1.26%SWTXSpringWorks Therapeutics$36.55-2.4%2.0472 of 5 stars3.00$67.00 83.3%7Analyst Forecast1.16%COGTCogent Biosciences$9.18+1.1%2.8854 of 5 stars2.71$14.83 61.6%7Analyst Revision1.09%SDGRSchrödinger$19.08-0.5%2.0033 of 5 stars2.82$32.90 72.4%110.97%MRNAModerna$36.72-0.6%4.6292 of 5 stars2.18$84.00 128.8%22Analyst UpgradeAnalyst Revision0.95%BNTXBioNTech$103.28+1.1%3.4857 of 5 stars2.81$138.79 34.4%16Analyst ForecastAnalyst Revision0.89%CGEMCullinan Therapeutics$12.25-2.6%1.8429 of 5 stars3.00$31.67 158.5%7Analyst Revision0.89%BCYCBicycle Therapeutics$20.11-1.2%2.8599 of 5 stars2.78$40.13 99.5%9Analyst Revision0.89%IDYAIDEAYA Biosciences$25.72+0.7%4.1494 of 5 stars2.94$53.67 108.7%16Analyst Forecast0.81%NRIXNurix Therapeutics$22.81+0.8%2.7301 of 5 stars2.93$29.40 28.9%150.76%ORICORIC Pharmaceuticals$8.73-0.1%4.1915 of 5 stars3.00$18.29 109.5%8Analyst Revision0.71%RLAYRelay Therapeutics$4.61-1.1%3.2798 of 5 stars2.90$21.22 360.4%100.68%IMCRImmunocore$32.19-0.7%3.012 of 5 stars2.62$69.18 114.9%13Positive News0.68%RCUSArcus Biosciences$14.31-2.1%2.6831 of 5 stars3.00$34.00 137.6%90.62%TERNTerns Pharmaceuticals$5.66+1.1%4.327 of 5 stars2.83$27.25 381.4%60.56%CGONCG Oncology$32.03-0.7%3.1675 of 5 stars3.11$63.88 99.4%9Short Interest ↓Analyst RevisionPositive News0.52%JSPRJasper Therapeutics$21.18+1.0%2.6633 of 5 stars3.00$74.86 253.4%90.50%ARVNArvinas$23.63+4.1%3.0807 of 5 stars2.93$61.08 158.5%14Analyst ForecastShort Interest ↓News Coverage0.48%CRBPCorbus Pharmaceuticals$16.52+2.7%4.8777 of 5 stars3.13$65.86 298.7%8Positive News This page (NASDAQ:CANC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts